Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphoma
Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Iyer SP, Shustov AR, Wolfson J, Balser BE, Coiffier B. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphoma. Hematological Oncology 2016, 35: 914-917. PMID: 27402335, PMCID: PMC5763404, DOI: 10.1002/hon.2320.Peer-Reviewed Original ResearchConceptsRefractory angioimmunoblastic T-cell lymphomaAngioimmunoblastic T-cell lymphomaT-cell lymphomaDurable responsesPatientsLymphomaRomidepsin